MovDisordV3, Main, Exploration, bibRecord, 003861

Long‐term botulinum toxin efficacy, safety, and immunogenicity

Identifieur interne : 003861 ( Main/Exploration ); précédent : 003860; suivant : 003862

Long‐term botulinum toxin efficacy, safety, and immunogenicity

Auteurs : Nicte I. Mejia [États-Unis] ; Kevin Dat Vuong [États-Unis] ; Joseph Jankovic [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2005-05.

RBID : ISTEX:A08BEA13AD969E46D86A18938D035D8BC021566A

Descripteurs français

Pascal (Inist)
- Bontoxilysin, Complication, Dystonie, Immunogénicité, Long terme, Système nerveux pathologie, Sécurité.

English descriptors

KwdEn :
- Aged, Antibodies (immunology), Blepharoptosis (drug therapy), Blepharoptosis (immunology), Blepharoptosis (physiopathology), Bontoxilysin, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (adverse effects), Botulinum Toxins, Type A (therapeutic use), Complication, Deglutition Disorders (drug therapy), Deglutition Disorders (immunology), Deglutition Disorders (physiopathology), Drug Administration Schedule, Dystonia, Dystonia (drug therapy), Dystonia (immunology), Dystonia (physiopathology), Female, Hemifacial Spasm (drug therapy), Hemifacial Spasm (immunology), Hemifacial Spasm (physiopathology), Humans, Immunogenicity, Injections, Long term, Male, Middle Aged, Muscle Weakness (drug therapy), Muscle Weakness (immunology), Muscle Weakness (physiopathology), Neck Muscles (physiopathology), Nervous system diseases, Neuromuscular Agents (administration & dosage), Neuromuscular Agents (adverse effects), Neuromuscular Agents (therapeutic use), Safety, Time Factors, botulinum toxin, complications, dystonia, efficacy, immunogenicity, long‐term.
MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , adverse effects : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , immunology : Antibodies.
- drug therapy : Blepharoptosis, Deglutition Disorders, Dystonia, Hemifacial Spasm, Muscle Weakness.
- immunology : Blepharoptosis, Deglutition Disorders, Dystonia, Hemifacial Spasm, Muscle Weakness.
- physiopathology : Blepharoptosis, Deglutition Disorders, Dystonia, Hemifacial Spasm, Muscle Weakness, Neck Muscles.
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- Aged, Drug Administration Schedule, Female, Humans, Injections, Male, Middle Aged, Time Factors.

Abstract

To determine the long‐term efficacy of botulinum toxin (BTX) treatments, we analyzed longitudinal follow‐up data on 45 patients (32 women; mean age, 68.8 years) currently followed in the Baylor College of Medicine Movement Disorders Clinic, who have received BTX treatments continuously for at least 12 years (mean 15.8 ± 1.5 years). Their mean response rating after the last injection, based one a previously described scale 0‐to‐4 scale (0 = no effect; 4 = marked improvement) was 3.7 ± 0.6 and the mean total duration of response was 15.4 ± 3.4 weeks. Although the latency and total duration of the response to treatment have not changed over time, the peak duration of response (P < 0.005) and dose per visit (P < 0.0001) have increased since the initial visit. Furthermore, global rating (P < 0.02) and peak effect (P < 0.05) have improved. In total, 20 adverse events occurred in 16 of 45 (35.6%) patients after their initial visit and 11 adverse events in 10 of 45 (22.2%) patients at their most recent injection visit. Antibody (Ab) testing was carried out in 22 patients due to nonresponsiveness; blocking Abs were confirmed by the mouse protection assay in 4 of 22 (18%) patients. Of the Ab‐negative patients, 16 resumed responsiveness after dose adjustments and2 persisted as nonrespondents. Except for 1 patient, the 4 Ab‐positive and the 2 clinical nonresponders are being treated with BTX‐B. This longest reported follow‐up of BTX injections confirms the long‐term efficacy and safety of this treatment. © 2005 Movement Disorder Society

Url:

https://api.istex.fr/document/A08BEA13AD969E46D86A18938D035D8BC021566A/fulltext/pdf

DOI: 10.1002/mds.20376

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term botulinum toxin efficacy, safety, and immunogenicity</title>
<author><name sortKey="Mejia, Nicte I" sort="Mejia, Nicte I" uniqKey="Mejia N" first="Nicte I." last="Mejia">Nicte I. Mejia</name>
</author>
<author><name sortKey="Vuong, Kevin Dat" sort="Vuong, Kevin Dat" uniqKey="Vuong K" first="Kevin Dat" last="Vuong">Kevin Dat Vuong</name>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A08BEA13AD969E46D86A18938D035D8BC021566A</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20376</idno>
<idno type="url">https://api.istex.fr/document/A08BEA13AD969E46D86A18938D035D8BC021566A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001195</idno>
<idno type="wicri:Area/Istex/Curation">001195</idno>
<idno type="wicri:Area/Istex/Checkpoint">002269</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Mejia N:long:term:botulinum</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15645481</idno>
<idno type="wicri:Area/PubMed/Corpus">003168</idno>
<idno type="wicri:Area/PubMed/Curation">003168</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003074</idno>
<idno type="wicri:Area/Ncbi/Merge">001133</idno>
<idno type="wicri:Area/Ncbi/Curation">001133</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001133</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Mejia N:long:term:botulinum</idno>
<idno type="wicri:Area/Main/Merge">004F46</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:05-0281345</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E89</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000E32</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001E05</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Mejia N:long:term:botulinum</idno>
<idno type="wicri:Area/Main/Merge">005283</idno>
<idno type="wicri:Area/Main/Curation">003861</idno>
<idno type="wicri:Area/Main/Exploration">003861</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term botulinum toxin efficacy, safety, and immunogenicity</title>
<author><name sortKey="Mejia, Nicte I" sort="Mejia, Nicte I" uniqKey="Mejia N" first="Nicte I." last="Mejia">Nicte I. Mejia</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vuong, Kevin Dat" sort="Vuong, Kevin Dat" uniqKey="Vuong K" first="Kevin Dat" last="Vuong">Kevin Dat Vuong</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-05">2005-05</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="592">592</biblScope>
<biblScope unit="page" to="597">597</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">A08BEA13AD969E46D86A18938D035D8BC021566A</idno>
<idno type="DOI">10.1002/mds.20376</idno>
<idno type="ArticleID">MDS20376</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antibodies (immunology)</term>
<term>Blepharoptosis (drug therapy)</term>
<term>Blepharoptosis (immunology)</term>
<term>Blepharoptosis (physiopathology)</term>
<term>Bontoxilysin</term>
<term>Botulinum Toxins, Type A (administration & dosage)</term>
<term>Botulinum Toxins, Type A (adverse effects)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Complication</term>
<term>Deglutition Disorders (drug therapy)</term>
<term>Deglutition Disorders (immunology)</term>
<term>Deglutition Disorders (physiopathology)</term>
<term>Drug Administration Schedule</term>
<term>Dystonia</term>
<term>Dystonia (drug therapy)</term>
<term>Dystonia (immunology)</term>
<term>Dystonia (physiopathology)</term>
<term>Female</term>
<term>Hemifacial Spasm (drug therapy)</term>
<term>Hemifacial Spasm (immunology)</term>
<term>Hemifacial Spasm (physiopathology)</term>
<term>Humans</term>
<term>Immunogenicity</term>
<term>Injections</term>
<term>Long term</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Muscle Weakness (drug therapy)</term>
<term>Muscle Weakness (immunology)</term>
<term>Muscle Weakness (physiopathology)</term>
<term>Neck Muscles (physiopathology)</term>
<term>Nervous system diseases</term>
<term>Neuromuscular Agents (administration & dosage)</term>
<term>Neuromuscular Agents (adverse effects)</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Safety</term>
<term>Time Factors</term>
<term>botulinum toxin</term>
<term>complications</term>
<term>dystonia</term>
<term>efficacy</term>
<term>immunogenicity</term>
<term>long‐term</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharoptosis</term>
<term>Deglutition Disorders</term>
<term>Dystonia</term>
<term>Hemifacial Spasm</term>
<term>Muscle Weakness</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Blepharoptosis</term>
<term>Deglutition Disorders</term>
<term>Dystonia</term>
<term>Hemifacial Spasm</term>
<term>Muscle Weakness</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Blepharoptosis</term>
<term>Deglutition Disorders</term>
<term>Dystonia</term>
<term>Hemifacial Spasm</term>
<term>Muscle Weakness</term>
<term>Neck Muscles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Injections</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term>
<term>Complication</term>
<term>Dystonie</term>
<term>Immunogénicité</term>
<term>Long terme</term>
<term>Système nerveux pathologie</term>
<term>Sécurité</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To determine the long‐term efficacy of botulinum toxin (BTX) treatments, we analyzed longitudinal follow‐up data on 45 patients (32 women; mean age, 68.8 years) currently followed in the Baylor College of Medicine Movement Disorders Clinic, who have received BTX treatments continuously for at least 12 years (mean 15.8 ± 1.5 years). Their mean response rating after the last injection, based one a previously described scale 0‐to‐4 scale (0 = no effect; 4 = marked improvement) was 3.7 ± 0.6 and the mean total duration of response was 15.4 ± 3.4 weeks. Although the latency and total duration of the response to treatment have not changed over time, the peak duration of response (P < 0.005) and dose per visit (P < 0.0001) have increased since the initial visit. Furthermore, global rating (P < 0.02) and peak effect (P < 0.05) have improved. In total, 20 adverse events occurred in 16 of 45 (35.6%) patients after their initial visit and 11 adverse events in 10 of 45 (22.2%) patients at their most recent injection visit. Antibody (Ab) testing was carried out in 22 patients due to nonresponsiveness; blocking Abs were confirmed by the mouse protection assay in 4 of 22 (18%) patients. Of the Ab‐negative patients, 16 resumed responsiveness after dose adjustments and2 persisted as nonrespondents. Except for 1 patient, the 4 Ab‐positive and the 2 clinical nonresponders are being treated with BTX‐B. This longest reported follow‐up of BTX injections confirms the long‐term efficacy and safety of this treatment. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
<settlement><li>Houston</li>
</settlement>
<orgName><li>Baylor College of Medicine</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Mejia, Nicte I" sort="Mejia, Nicte I" uniqKey="Mejia N" first="Nicte I." last="Mejia">Nicte I. Mejia</name>
</region>
<name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<name sortKey="Vuong, Kevin Dat" sort="Vuong, Kevin Dat" uniqKey="Vuong K" first="Kevin Dat" last="Vuong">Kevin Dat Vuong</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003861 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003861 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A08BEA13AD969E46D86A18938D035D8BC021566A
   |texte=   Long‐term botulinum toxin efficacy, safety, and immunogenicity
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Long‐term botulinum toxin efficacy, safety, and immunogenicity

Long‐term botulinum toxin efficacy, safety, and immunogenicity

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.